HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

All News

GnRH Agonists for Prostate Cancer Could Increase CVD Risk in Type 2 Diabetes

August 09, 2022

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

MYFEMBREE Scores FDA Approval for Endometriosis Pain

August 06, 2022

On August 5, Pfizer announced the FDA's approval of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the management of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.

Blood Protein Could Signal Increased Risk of Diabetes, Future Cancer Mortality

August 05, 2022

An analysis of more than 20 years of follow-up data from more than 4000 patients in the Malmö Diet and Cancer Study shed light on associations between prostasin concentrations and risk of developing diabetes and cancer mortality.

Women's Preventive Services Initiative Releases Guidance for Preventing Obesity in Midlife

August 04, 2022

A national coalition of more than 20 health professional organizations and patient representatives, the WPSI recommendation for preventing obesity in midlife women advocates for counseling to maintain weight or limit weight gain among women with normal or overweight BMI aged 40-60 years.

Poor Sleep Habits, Behaviors Could Increase Risk of Fatty Liver Disease

August 01, 2022

An analysis of a prospective cohort study in China provides evidence suggesting poor sleep behaviors, including daytime napping and nighttime sleep disturbances, could increase risk of metabolic dysfunction-associated fatty liver disease.

Endocrine Month in Review: July 2022

July 30, 2022

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.